Supplementary Figure S9 from GPSai: A Clinically Validated AI Tool for Tissue of Origin Prediction during Routine Tumor Profiling

Hassan Ghani; Anthony Helmstetter; Jennifer R. Ribeiro; Todd Maney; Stephanie Rock; Rebecca Feldman; Jeffrey Swensen; Farah Abdulla; David Spetzler; Elena Florento; Ari M. Vanderwalde; Patricia Pittman; Milan Radovich; Jaclyn F. Hechtman; Casey Bales; George W. Sledge; Myra M. George; David Bryant; Jim Abraham; Matthew J. Oberley

doi:10.1158/2767-9764.30021980

Key Points

GPSai changes drug eligibility in tumor profiling, stressing its importance in clinical decision-making.
Cases showed added eligibility for treatment based on GPSai results, impacting patient management.
Observational analysis assessed the influence of diagnostic and biomarker data on drug eligibility.
This analysis suggests a need for further validation, potentially shaping future guidelines for treatment.

Implication

Observational analysis reveals changes in drug eligibility based on GPSai's tissue origin predictions, highlighting its clinical relevance.

Abstract

Changes in drug eligibility based on GPSai results. Based on diagnosis & biomarker or diagnosis-only, all cases with added eligibility (a) or ineligibility (b) for the indicated drugs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ghani et al. (2025) studied this question.

synapsesocial.com/papers/68bb49cc6d6d5674bccffad7 https://doi.org/10.1158/2767-9764.30021980

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S9 from GPSai: A Clinically Validated AI Tool for Tissue of Origin Prediction during Routine Tumor Profiling

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S9 from GPSai: A Clinically Validated AI Tool for Tissue of Origin Prediction during Routine Tumor Profiling

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading